NCT06547099 · RECRUITING
Study to Understand Novel Biomarkers in Researching Dementia
This study is testing how well blood tests can detect Alzheimer's-related changes, including amyloid, tau, and nerve cell damage. Researchers compare blood results with brain scans, memory tests, and diagnoses over time. No drug is given. It is an observational biomarker study with no assigned phase, so it is about better diagnostics, not a treatment.
You may qualify if
- At least 60 years of age
- 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
- All SEABIRD participants will be invited to participate regardless of their cognitive status
You're excluded if
- Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
- Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
- Taking a disease-modifying drug for AD at time of enrollment
- Blood transfusion in the last three months
- Unwilling or unable to participate in all study activities
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-09-11